Chemomab Therapeutics (CMMB) Income from Continuing Operations (2017 - 2025)
Chemomab Therapeutics (CMMB) posted Income from Continuing Operations of 625680763000.0 for Q4 2025, up 35917280.2% on a QoQ basis from 1742000.0 in Q3 2025, and up 65.9% year-over-year from 377132220000.0 in Q4 2024.
Chemomab Therapeutics (CMMB) Income from Continuing Operations (2017 - 2025) Analysis & Trends
Chemomab Therapeutics' Income from Continuing Operations history runs 9 years deep, the most recent figure standing at 625680763000.0 for Q4 2025.
- Quarterly Income from Continuing Operations rose 65.9% year-over-year to 625680763000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 1002818208000.0 (up 165.9% YoY) and the FY2025 annual result came in at 8995000.0, up 35.5% from the prior year.
- Income from Continuing Operations was 625680763000.0 for Q4 2025 at Chemomab Therapeutics, up from 1742000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 625680763000.0 in Q4 2025 and bottomed at 5104000.0 in Q1 2022.
- A 5-year average of 55714219777.78 and a median of 3749500.0 in 2024 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations tumbled 199.53% — and 2024, when it jumped 11036839.42%.
- Chemomab Therapeutics' Income from Continuing Operations stood at 5036000.0 in 2021, then jumped by 263.86% to 8252000.0 in 2022, then slumped by 58.59% to 3417000.0 in 2023, then soared by 11036839.42% to 377132220000.0 in 2024, then surged by 65.9% to 625680763000.0 in 2025.
- Business Quant data shows CMMB's Income from Continuing Operations at 625680763000.0 in Q4 2025, 1742000.0 in Q3 2025, and 377132220000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Chemomab Therapeutics | 124.14 Mn | 113.77 Mn | - | 625.68 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 625.68 Bn |
| Sep 30, 2025 | 1.74 Mn |
| Dec 31, 2024 | 377.13 Bn |
| Sep 30, 2024 | 3.48 Mn |
| Jun 30, 2024 | 3.63 Mn |
| Mar 31, 2024 | 3.87 Mn |
| Dec 31, 2023 | 3.42 Mn |
| Sep 30, 2023 | 4.19 Mn |
| Jun 30, 2023 | 7.90 Mn |
| Mar 31, 2023 | 8.71 Mn |
| Dec 31, 2022 | 8.25 Mn |
| Sep 30, 2022 | 8.08 Mn |
| Jun 30, 2022 | 7.28 Mn |
| Mar 31, 2022 | -5.10 Mn |
| Dec 31, 2021 | -5.04 Mn |
| Sep 30, 2021 | -2.97 Mn |
| Jun 30, 2021 | -2.77 Mn |
| Mar 31, 2021 | -1.70 Mn |
| Dec 31, 2020 | -6.38 Mn |
| Sep 30, 2020 | -2.45 Mn |